U.S. Markets closed

AN2 Therapeutics, Inc. (ANTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.75-0.03 (-0.34%)
At close: 04:00PM EDT
8.75 0.00 (0.00%)
After hours: 05:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.78
Bid8.58 x 800
Ask8.75 x 900
Day's Range8.41 - 9.85
52 Week Range7.43 - 23.58
Avg. Volume81,041
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.67
  • GlobeNewswire

    AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

    On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Begin in First Half of 2022 AN2 Board Strengthened through Appointment of Key Industry Executives MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical com

  • Business Wire

    AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

    MENLO PARK, Calif., May 09, 2022--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors.

  • American City Business Journals

    Here are the Bay Area's biggest startup exits of the first quarter

    The collective valuation of the 10 biggest first quarter exits of 2022 among local companies was less than a tenth of that of the top 10 from the same period last year.